Imlunestrant

Last Updated: 04/28/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications

A Systematic Review of Major Advances in Breast Cancer Therapeutics in 2025: Synthesis of Conference and Published Evidence.

A Systematic Review of Major Advances in Breast Cancer Therapeutics in 2025: Synthesis of Conference and Published Evidence.

Journal: International journal of molecular sciences
Published: January 25, 2026

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; imlunestrant for breast cancer, tafasitamab for follicular lymphoma, atezolizumab for thymic carcinoma, retifanlimab for anal canal squamous cell carcinoma, and tagraxofusp for blastic plasmacytoid dendritic cell neoplasm.

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; imlunestrant for breast cancer, tafasitamab for follicular lymphoma, atezolizumab for thymic carcinoma, retifanlimab for anal canal squamous cell carcinoma, and tagraxofusp for blastic plasmacytoid dendritic cell neoplasm.

Journal: International journal of clinical oncology
Published: January 08, 2026

Imlunestrant (Inluriyo) for advanced breast cancer.

Imlunestrant (Inluriyo) for advanced breast cancer.

Journal: The Medical letter on drugs and therapeutics
Published: January 08, 2026

Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial.

Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial.

Journal: ESMO open
Published: January 05, 2026

Imlunestrant in ER+ advanced breast cancer - bridging innovation and clinical reality.

Imlunestrant in ER+ advanced breast cancer - bridging innovation and clinical reality.

Journal: Annals of medicine and surgery (2012)
Published: November 11, 2025

Inluriyo (imlunestrant) for ESR1-mutant breast cancer: modest gains, unmet concerns.

Inluriyo (imlunestrant) for ESR1-mutant breast cancer: modest gains, unmet concerns.

Journal: Annals of medicine and surgery (2012)
Published: November 04, 2025

Imlunestrant: First Approval.

Imlunestrant: First Approval.

Journal: Drugs
Published: October 23, 2025

Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial.

Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 07, 2025

Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trials.

Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trials.

Journal: ESMO open
Published: August 25, 2025

Imlunestrant significantly improves PFS for patients with advanced breast cancer.

Imlunestrant significantly improves PFS for patients with advanced breast cancer.

Journal: Cancer
Published: July 03, 2025

Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a/1b EMBER study.

Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a/1b EMBER study.

Journal: Breast cancer research : BCR
Published: June 09, 2025

Phase 1 Study Evaluating the Effect of Food and Omeprazole-Induced Gastric pH Change on the Pharmacokinetics and Safety of Imlunestrant in Healthy Females.

Phase 1 Study Evaluating the Effect of Food and Omeprazole-Induced Gastric pH Change on the Pharmacokinetics and Safety of Imlunestrant in Healthy Females.

Journal: Clinical therapeutics
Published: February 25, 2025
Showing 1-12 of 25

Last Updated: 04/28/2026